The authors of this Article have requested that it be retracted. During attempts to scale up the experiments for clinical studies, we could not reproduce the apoptosis (Figure 4) and cell cycle distribution results reported in the paper. We carried out a detailed intra-departmental investigation and found that the equivalent concentrations of cisplatin (CDDP) in the nanoparticles (PLD) had been miscalculated, and that the MG63 cells were cross-contaminated, leading to significant errors in the experimental results.
All the authors recognize that these errors have affected the validity of the Article and have agreed to retraction. The authors apologize for their carelessness.
Additional information
The online version of the original article can be found at 10.1038/srep17387
Rights and permissions
This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
About this article
Cite this article
Liu, P., Sun, L., Zhou, Ds. et al. Retraction Note: Development of Alendronate-conjugated Poly (lactic-co-glycolic acid)-Dextran Nanoparticles for Active Targeting of Cisplatin in Osteosarcoma. Sci Rep 6, 31938 (2016). https://doi.org/10.1038/srep31938
Published:
DOI: https://doi.org/10.1038/srep31938
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.
